Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. [electronic resource]
Producer: 20090219Description: 473-81 p. digitalISSN:- 1474-547X
- Blood Glucose -- drug effects
- Blood Pressure -- drug effects
- Diabetes Mellitus, Type 2 -- drug therapy
- Double-Blind Method
- Female
- Glucagon-Like Peptide 1 -- adverse effects
- Glycated Hemoglobin -- drug effects
- Humans
- Hypoglycemic Agents -- adverse effects
- Liraglutide
- Male
- Middle Aged
- Sulfonylurea Compounds -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.